Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes.

Diabetes technology & therapeutics·2025
Same author

Peptide hormones and bile acids shaping immune tolerance of the liver: implications and applications.

Protein & cell·2025
Same author

Beyond metabolic benefits: The underexplored immunomodulatory effects of GLP-1/glucagon agonists.

Journal of hepatology·2025
Same author

One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.

Diabetologia·2025
Same author

Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.

Journal of pediatric gastroenterology and nutrition·2024
Same author

Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study.

Diabetes care·2020

Related Experiment Videos

Statins in hepatobiliary diseases: effects, indications and risks.

Ine Lowyck1, Johan Fevery

  • 1Department of Hepatology, UZ Gasthuisberg, Leuven. Ine.Lowyck@uz.kuleuven.be

Acta Gastro-Enterologica Belgica
|March 12, 2008
PubMed
Summary

Statins offer cardiovascular benefits but their use in liver diseases like Primary Biliary Cirrhosis requires careful consideration due to potential contraindications and specific lipid profiles.

Area of Science:

  • Hepatology
  • Cardiology
  • Pharmacology

Background:

  • Statins are widely prescribed medications with known cardiovascular benefits.
  • This study investigates the indications and contraindications of statin use in patients with hepatobiliary diseases.
  • A case of Primary Biliary Cirrhosis (PBC) with hypercholesterolemia and cardiac issues prompted this research.

Observation:

  • Statins provide lipid-lowering effects, prevent atherosclerosis, reduce diabetes risk, and inhibit fibrogenesis.
  • Statin efficacy and side effects (myopathy, liver toxicity) vary based on drug type, patient characteristics, and interactions.
  • Statin use in liver disease is not well-defined; fibrates may be preferred for Non-Alcoholic Fatty Liver Disease (NAFLD).

Findings:

  • Atorvastatin and pravastatin show preliminary promise for NAFLD improvement.

Related Experiment Videos

  • Statin use for gallstones is unclear, though combination therapy with ursodeoxycholic acid may help mixed stones.
  • Statin therapy is often not indicated in Primary Biliary Cirrhosis due to protective Lipoprotein X particles and high HDL-cholesterol.

    • Implications:

    • Cardiovascular issues in chronic cholestasis warrant investigation into underlying factors.
    • Lipid abnormalities in PBC are stage-dependent, influencing treatment decisions.
    • Further research is needed to clarify optimal statin use in various hepatobiliary conditions.